公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting | Reck M.; Garassino M.C.; Imbimbo M.; Shepherd F.A.; Socinski M.A.; JIN-YUAN SHIH ; Tsao A.; Lee P.; Winfree K.B.; Sashegyi A.; Cheng R.; Varea R.; Levy B.; Garon E. | Lung Cancer | 28 | 25 | |
2013 | Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers | Chou A.-H.; Liu C.-C.; Chang J.-Y.; Jiang R.; Hsieh Y.-C.; Tsao A.; Wu C.-L.; Huang J.-L.; Fung C.-P.; SZU-MIN HSIEH ; Wang Y.-F.; Wang J.-R.; Hu M.-H.; Chiang J.-R.; Su I.-J.; Chong P.C.-S. | PLoS ONE | 79 | 65 |